Venetoclax consolidation after BTKi based therapy for patients with CLL

被引：0
|
作者：
Heyman, Benjamin
Choi, Michael
Kipps, Thomas
机构：
来源：
LEUKEMIA & LYMPHOMA | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1549155
引用
收藏
页码：S67 / S68
页数：2
相关论文
共 50 条
  • [1] Relapse After Frontline BTKi Therapy in Patients with CLL: Options and Consideration
    Lamanna, Nicole
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S40 - S42
  • [2] Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax
    Heyman, Benjamin
    Choi, Michael Y.
    Ghia, Emanuela M.
    Widhopf, George F., II
    Pu, Minya
    Pittman, Emily
    Messer, Karen
    Jamieson, Catriona
    Kipps, Thomas J.
    [J]. BLOOD, 2020, 136
  • [3] Durable efficacy with fixed-duration BTKi and venetoclax for CLL
    Nierengarten, Mary Beth
    [J]. CANCER, 2024, 130 (19)
  • [4] BTKi in CLL Therapy: yesterday, today and Future
    不详
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (7-8) : 458 - 459
  • [5] Zanubrutinib and venetoclax as initial therapy for CLL with obinutuzumab triplet consolidation in patients with minimal residual disease positivity (BruVenG)
    Allan, John
    Helbig, Daniel
    Rutherford, Sarah
    Mulvey, Erin
    Greig, Katie
    Stewart, Sandra
    LaPinta, Melissa
    Rudolph, Leslie
    Agami, Orel
    Bernstein, Melanie
    Ruan, Jia
    Leonard, John
    Martin, Peter
    Furman, Richard
    [J]. LEUKEMIA & LYMPHOMA, 2023, 64 : S45 - S46
  • [6] Zanubrutinib and Venetoclax As Initial Therapy for CLL/SLL with Obinutuzumab Triplet Consolidation in Patients with Minimal Residual Disease Positivity (BruVenG)
    Allan, John N.
    Helbig, Daniel
    Mulvey, Erin
    Nazir, Sarah
    Stewart, Sandra
    Lapinta, Melissa L.
    Rutherford, Sarah C.
    Ruan, Jia
    Leonard, John P.
    Martin, Peter
    Furman, Richard R.
    [J]. BLOOD, 2023, 142
  • [7] BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax
    Lin, Victor S.
    Lew, Thomas E.
    Handunnetti, Sasanka M.
    Blombery, Piers
    Nguyen, Tamia
    Westerman, David A.
    Kuss, Bryone J.
    Tam, Constantine S.
    Roberts, Andrew W.
    Seymour, John F.
    Anderson, Mary Ann
    [J]. BLOOD, 2020, 135 (25) : 2266 - 2270
  • [8] Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon
    Lew, Thomas E.
    Bennett, Rory
    Lin, Victor S.
    Whitechurch, Ashley
    Handunnetti, Sasanka M.
    Marlton, Paula
    Shen, Yandong
    Mulligan, Stephen P.
    Casan, Joshua
    Blombery, Piers
    Tam, Constantine S.
    Roberts, Andrew W.
    Seymour, John F.
    Thompson, Philip A.
    Anderson, Mary A.
    [J]. BLOOD ADVANCES, 2024, 8 (06) : 1439 - 1443
  • [9] Venetoclax Re-Treatment of Chronic Lymphocytic Leukemia (CLL) Patients after a Previous Venetoclax-Based Regimen
    Thompson, Meghan C.
    Allan, John N.
    Sail, Kavita
    Manzoor, Beenish S.
    Pu, Jeffrey J.
    Barr, Paul M.
    Coombs, Catherine C.
    Schuster, Stephen J.
    Skarbnik, Alan
    Rhodes, Joanna M.
    Barrientos, Jacqueline C.
    Roeker, Lindsey E.
    Leslie, Lori A.
    Kamdar, Manali
    Choi, Michael Y.
    Simkovic, Martin
    Lansigan, Frederick
    Hale, Brittany Jane
    Zelenetz, Andrew D.
    Moskowitz, Alison J.
    Bantilan, Kurt S.
    Komari, Celina J.
    Goy, Andre H.
    Feldman, Tatyana A.
    [J]. BLOOD, 2020, 136
  • [10] Venetoclax after idelalisib: relevant progress for CLL
    Bosch, Francesc
    Hallek, Michael
    [J]. BLOOD, 2018, 131 (15) : 1632 - 1633
12345